TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a clinical-stage company pioneering immuno-oncology and RNA for the treatment of high-risk and advanced cancer, announced the retirement of Chief Financial Officer Tom Fitzgerald, effective immediately. Fitzgerald, who has served as CFO since July 2018 and also served as a director, will continue to provide transition services to ensure a smooth handover.
In his place, the company has appointed John Tattory as interim CFO, effective immediately. Tattory brings more than 25 years of financial and operational management and leadership experience across the pharmaceutical, medical device, and biotechnology sectors. His career includes roles at Ernst & Young LLP, Bristol-Myers Squibb, Tyco International, Cerapedics, and Windtree Therapeutics. Currently, he serves as a managing director at Stout Risius Ross, where he provides consulting CFO services primarily to privately held life science companies.
The leadership change comes at a critical time for TransCode Therapeutics as it continues to develop its pipeline of innovative cancer treatments. The company’s lead therapeutic candidate, TTX-MC138, targets metastatic tumors that overexpress microRNA-10b, a well-documented biomarker of metastasis. In addition, TransCode has a portfolio of other first-in-class therapeutic candidates designed to mobilize the immune system to recognize and destroy cancer cells.
For investors and stakeholders, the appointment of an interim CFO with Tattory’s depth of experience in life sciences finance is a reassuring signal. His background in both large pharmaceutical companies and smaller biotechs, combined with his consulting expertise, positions him to manage the financial complexities of a clinical-stage company. As TransCode advances its clinical programs, having a steady hand in the CFO role is essential for maintaining financial discipline and supporting strategic initiatives.
The transition also highlights the company’s commitment to continuity. Fitzgerald’s willingness to provide transition services indicates a thoughtful succession process, which can help mitigate potential disruptions. The market often reacts to executive changes with uncertainty, but the immediate appointment of a seasoned interim CFO may alleviate concerns.
TransCode Therapeutics remains focused on its mission to develop breakthrough treatments for high-risk and advanced cancers. The company’s innovative approach, combining immuno-oncology and RNA therapeutics, addresses significant unmet needs in oncology. With Tattory on board, the company is well-positioned to navigate the financial landscape while pursuing its clinical and regulatory milestones.
For more information, the full press release is available at https://nnw.fm/8G3ik. Investors can also stay updated on the latest news and updates relating to RNAZ in the company’s newsroom at https://nnw.fm/RNAZ.
